Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO David Ricks told investors “2026 is off to a strong start,

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they contain the same active ingredient, tirzepatide, and may affect blood sugar regulation and weight,

LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.

The once‑weekly “triple hormone” injection outperformed blockbuster drugs like Wegovy and Zepbound but caused more gastrointestinal side effects at higher doses and has yet to undergo peer review or secure regulatory approval.

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of effectiveness, side effects, average costs and the best online weight loss medication platforms to buy them.

Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, while also committing an additional US$4.